BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

Rhea-AI Summary

BioNexus Gene Lab (Nasdaq: BGLC) has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This achievement strengthens the company's position as a compliant public entity and supports its growth initiatives.

The biotechnology company, specializing in precision diagnostics and specialty chemicals, is pursuing a dual-focus strategy through:

• MRNA Scientific - Expanding RNA-based genomic diagnostics and non-invasive blood tests for 11 major diseases
• Chemrex - Scaling specialty materials operations in Southeast Asia with focus on sustainable development

Under CEO Sam Tan's leadership, BioNexus has enhanced its corporate governance by appointing new independent board members, establishing an internal audit function, and securing U.S.-based investment banking support. These measures position the company for strategic partnerships, capital raising, and M&A opportunities while maintaining its valuable Nasdaq listing status.

Positive

• Regained Nasdaq compliance by meeting minimum $1.00 bid price requirement
• Maintained strategic Nasdaq listing enabling global visibility and institutional capital access
• Advancing RNA-based genomic diagnostics with potential new products
• Expanding non-invasive blood tests screening for 11 major diseases
• Growing specialty materials business Chemrex in Southeast Asia
• Strengthened corporate governance with new independent board members
• Established internal audit function
• Secured U.S. investment banking support

Negative

• Previous non-compliance with Nasdaq listing requirements suggests recent stock price weakness
• Need for enhanced corporate governance indicates potential past deficiencies
• Multiple business segments may indicate lack of focused strategy

Insights

Financial Analyst

Regaining Nasdaq compliance removes delisting risk and positions BGLC for strategic growth initiatives and improved capital market access.

BioNexus Gene Lab Corp.'s announcement of regaining compliance with Nasdaq's $1.00 minimum bid price requirement represents a critical regulatory milestone that removes a significant risk factor. For small-cap biotechnology companies, maintaining Nasdaq listing status is essential for visibility, liquidity, and institutional investor access.

The company operates through two distinct business segments: MRNA Scientific, focused on RNA-based genomic diagnostics including non-invasive blood tests for disease screening, and Chemrex, a specialty materials subsidiary serving Southeast Asia's chemical raw materials market. The strategic focus mentions expansion opportunities in both divisions, though specific financial metrics and growth targets aren't provided.

Particularly noteworthy are the corporate governance enhancements, including new independent board members, a dedicated internal audit function, and engagement with U.S.-based investment banking support. These structural improvements typically precede capital raising activities, strategic partnerships, or potential M&A initiatives.

The successful resolution of the Nasdaq compliance issue signals management effectiveness in addressing regulatory challenges while maintaining focus on operational growth strategies. For existing shareholders, this development preserves the value proposition of market access and liquidity that comes with Nasdaq listing status.

Corporate Governance Expert

BGLC's governance enhancements alongside Nasdaq compliance signal institutional-grade operational readiness and improved investor protection.

The corporate governance improvements detailed in BioNexus Gene Lab's announcement represent substantive structural enhancements that extend beyond mere Nasdaq compliance. The addition of new independent board members strengthens oversight capabilities and introduces valuable external perspectives to strategic decision-making processes.

The establishment of a dedicated internal audit function indicates a commitment to robust financial controls, transparency, and risk management - critical elements for companies pursuing growth strategies across international markets. This function typically oversees compliance with financial reporting standards and regulatory requirements across jurisdictions.

The retention of U.S.-based investment banking support signals preparation for potential capital market activities while ensuring governance practices align with institutional investor expectations. This third-party engagement provides additional credibility to the company's financial communication and strategic planning processes.

These governance enhancements, implemented in parallel with resolving the Nasdaq listing requirement, demonstrate a holistic approach to corporate maturity rather than simply addressing the immediate compliance issue. For stakeholders, this represents a meaningful commitment to sustainable business practices and shareholder protection frameworks that support long-term value creation objectives.

KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

This important milestone reaffirms the Company’s standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capital market engagement, and international expansion.

“This achievement is more than a compliance milestone - it’s a signal to the market that BGLC is strategically aligned, financially resilient, and fully prepared to capitalize on future growth opportunities,” said Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp. “Our Nasdaq listing continues to be a cornerstone of our long-term strategy, enabling global visibility, investor confidence, and access to institutional capital. We’re excited to move forward from this position of strength.”

A Platform for Innovation and Global Reach

BioNexus Gene Lab Corp. is advancing a multi-pronged strategy centered on:

• Expanding its RNA-based genomic diagnostics business, MRNA Scientific, including strategic partnerships and the potential to bring on new products, and driving adoption of its non-invasive blood tests that screen for 11 major diseases.
• Scaling its specialty materials subsidiary, Chemrex, which currently serves Southeast Asia’s growing demand for high-performance chemical raw materials, into new areas of sustainable development, and growth in upstream and downstream production.

Reinforced Corporate Governance and Market Readiness

In parallel with achieving Nasdaq compliance, BGLC has taken decisive steps to strengthen corporate governance, enhance internal controls, and position itself for strategic partnerships, capital raising, and M&A activity. This includes the appointment of new independent board members, the formation of a dedicated internal audit function, and the retention of U.S.-based investment banking support for long-term value creation initiatives.

“Our continued Nasdaq listing reflects our governance maturity and sets the foundation for scaling BGLC into a regionally integrated, innovation-driven enterprise,” said Tan. “We are grateful to our shareholders, advisors, and team members for their continued belief in our vision.”

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a Wyoming-incorporated biotechnology and specialty materials company with operations across Malaysia and Southeast Asia. The Company is a pioneer in RNA-based blood diagnostics, and a leading supplier of industrial chemical raw materials. BGLC is committed to delivering cutting-edge healthcare diagnostics, sustainable materials, and digital asset innovation to improve lives and build shareholder value.

For more information, visit: www.bionexusgenelab.com

Investor Relations Contact:
Email: ir@bionexusgenelab.com
Phone: +1 307 241 6898

FAQ

Why did BioNexus Gene Lab (BGLC) regain Nasdaq compliance in April 2025?

BioNexus Gene Lab regained Nasdaq compliance by meeting the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), demonstrating improved financial stability and market performance.

What are the main business divisions of BioNexus Gene Lab (BGLC) in 2025?

BioNexus Gene Lab operates two main divisions: MRNA Scientific, focusing on RNA-based genomic diagnostics and blood tests for 11 diseases, and Chemrex, which provides specialty chemical raw materials in Southeast Asia.

How is BioNexus Gene Lab (BGLC) strengthening its corporate governance in 2025?

BioNexus Gene Lab is strengthening governance through new independent board members, establishing an internal audit function, and partnering with U.S.-based investment banks for value creation initiatives.

What is BioNexus Gene Lab's (BGLC) expansion strategy after Nasdaq compliance?

BioNexus Gene Lab plans to expand its RNA diagnostics business through strategic partnerships, introduce new products, and scale its Chemrex subsidiary into sustainable development and production growth.

What does BGLC's Nasdaq compliance mean for investors?

BGLC's Nasdaq compliance ensures continued global visibility, maintains investor confidence, provides access to institutional capital, and positions the company for future growth opportunities and strategic initiatives.